Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.

Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.

The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.

The company is headquartered in Boston, Massachusetts.

Akari Therapeutics, Plc

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	12
CEO	Samir Patel

Contact Details

Address: 22 Boston Wharf Road, Floor 7 Boston, Massachusetts 02210 United States
Phone	929 274 7510
Website	akaritx.com

Stock Details

Ticker Symbol	AKTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001541157
CUSIP Number	00972G108
ISIN Number	US00972G2075
Employer ID	98-1034922
SIC Code	2834

Key Executives

Name	Position
Dr. Samir Rashmikant Patel M.D.	Interim President, Chief Executive Officer and Director
Wendy F. DiCicco CPA	Interim Chief Financial Officer
Dr. Miles Nunn	Chief Scientific Officer

Latest SEC Filings

Date	Type	Title
Dec 18, 2024	8-K	Current Report
Dec 16, 2024	8-K	Current Report
Dec 12, 2024	8-K	Current Report
Dec 6, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Nov 19, 2024	10-Q	Quarterly Report
Nov 15, 2024	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Nov 14, 2024	8-K	Current Report
Nov 8, 2024	8-K	Current Report
Oct 15, 2024	425	Filing
Oct 11, 2024	EFFECT	Notice of Effectiveness

View All SEC Filings